Crispr Therapeutics Ag (CRSP) Stock Price, Quote & News

Company Profile

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therap...

Industry: Biotechnology

Sector: Healthcare

Phone: 41 41 561 32 77

Website: www.crisprtx.com

Address:

Baarerstrasse 14, Zug, Switzerland

DinoFire Jul. 9 at 8:55 PM

$CRSP Patience is bitter, but its fruit is sweet.

0 · Reply

dens214 Jul. 9 at 8:37 PM

$CRSP H2,2026 day 9, 1/2 (vrtx) catalyst. Minimum positive price action.

0 · Reply

handmedown1 Jul. 9 at 8:16 PM

$CRSP Cant believe no activist investor has done anything. Is CW still holding?? She is kiss of death

0 · Reply

handmedown1 Jul. 9 at 8:14 PM

$CRSP such garbage

0 · Reply

TitsMcGeee Jul. 9 at 7:33 PM

$CRSP Buy in $40S, sell in $60S. A tale as old as time. I could have retired on trading this strategy for the last 5 years if I had any brain at all.

1 · Reply

brodobagginz Jul. 9 at 7:30 PM

$CRSP lame, lame, lame today

0 · Reply

dens214 Jul. 9 at 7:06 PM

$CRSP time for a stock buyback.

0 · Reply

BobJohnBuoy666 Jul. 9 at 4:41 PM

$CRSP needs to prove itself but as long as it stays north of the 200EMA looks to be setting up for a substantial breakout

0 · Reply

ultraviolin Jul. 9 at 4:20 PM

$CRSP $PFE Will re-enter $CRSP once it drops further

0 · Reply

handmedown1 Jul. 9 at 3:10 PM

$TWST $CRSP if only crspr had competent mgmt we would be on par with twist

0 · Reply

CRISPR Therapeutics (CRSP) Price Forecast: Dual Breakout Targets Higher Prices

Jun 24, 2026, 7:41 AM EDT - 15 days ago

3 Companies Redefining Healthcare Innovation

CMPS VRTX

Jun 17, 2026, 12:30 PM EDT - 22 days ago

The Healthcare M&A Wave

ABT ALNY AMGN AMRX ANTX AZN BDX

2026-06-11T10:22:50.000Z - 4 weeks ago

Crispr Therapeutics assumed at Equal Weight from Underweight at Morgan Stanley

Jun 9, 2026, 2:40 PM EDT - 4 weeks ago

CRISPR Therapeutics AG Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 3, 2026, 5:40 PM EDT - 5 weeks ago

CRISPR Therapeutics AG Transcript: 46th Annual William Blair Growth Stock Conference

Jun 3, 2026, 9:55 AM EDT - 5 weeks ago

CRISPR Therapeutics AG Transcript: Jefferies Global Healthcare Conference 2026

May 28, 2026, 8:00 AM EDT - 6 weeks ago

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

2026-05-13T10:36:49.000Z - 2 months ago

Crispr Therapeutics price target raised to $56 from $50 at Bernstein

May 12, 2026, 4:40 PM EDT - 2 months ago

CRISPR Therapeutics AG Transcript: Bank of America Global Healthcare Conference 2026

2026-05-11T16:48:13.000Z - 2 months ago

Crispr Therapeutics price target raised to $76 from $74 at Evercore ISI

2026-05-07T08:40:23.000Z - 2 months ago

Crispr Therapeutics price target raised to $82 from $80 at Citi

May 6, 2026, 8:30 AM EDT - 2 months ago

CRISPR Therapeutics to Present at the Bank of America Securities 2026 Global Healthcare Conference

2026-05-05T13:15:05.000Z - 2 months ago

Crispr Therapeutics price target lowered to $83 from $86 at BofA

2026-05-04T20:48:53.000Z - 2 months ago

Crispr Therapeutics reports Q1 EPS ($1.28), consensus ($1.23)

May 4, 2026, 4:30 PM EDT - 2 months ago

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results

May 4, 2026, 4:00 PM EDT - 2 months ago

CRISPR Therapeutics AG Earnings release: Q1 2026

May 4, 2026, 4:00 PM EDT - 2 months ago

CRISPR Therapeutics AG Quarterly report: Q1 2026

Apr 21, 2026, 8:00 AM EDT - 2 months ago

CRISPR Therapeutics AG Proxy statement: Proxy filing

Apr 21, 2026, 8:00 AM EDT - 2 months ago

CRISPR Therapeutics AG Proxy statement: Proxy filing

Apr 13, 2026, 2:15 PM EDT - 3 months ago

CRISPR Therapeutics AG Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 9, 2026, 1:35 PM EDT - 3 months ago

Wall Street Is Completely Wrong About These 5 Stocks

HPQ HUT NVDA RCL

Apr 7, 2026, 8:00 AM EDT - 3 months ago

CRISPR Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference

Apr 2, 2026, 8:00 AM EDT - 3 months ago

CRISPR Therapeutics AG Proxy statement: Proxy filing

2026-03-17T10:56:30.000Z - 4 months ago

Crispr Therapeutics price target raised to $110 from $105 at Piper Sandler

2026-03-13T00:55:12.000Z - 4 months ago

Cathie Wood’s ARK Investment buys 113K shares of Crispr Therapeutics today

2026-03-11T11:16:20.000Z - 4 months ago

Crispr Therapeutics prices upsized convertible senior notes offering

Mar 11, 2026, 7:00 AM EDT - 4 months ago

CRISPR Therapeutics Prices Upsized Convertible Senior Notes Offering

2026-03-11T01:05:09.000Z - 4 months ago

Cathie Wood’s ARK Investment buys 281K shares of Crispr Therapeutics today

2026-03-10T16:05:15.000Z - 4 months ago

Crispr Therapeutics falls -9.2%

Mar 10, 2026, 7:00 AM EDT - 4 months ago

CRISPR Therapeutics Announces Proposed Convertible Senior Notes Offering

Mar 2, 2026, 11:10 AM EST - 4 months ago

CRISPR Therapeutics AG Transcript: TD Cowen 46th Annual Health Care Conference

Feb 18, 2026, 10:45 AM EST - 5 months ago

CRISPR Therapeutics AG Transcript: Citi’s 2026 Virtual Oncology Leadership Summit

Feb 12, 2026, 4:30 PM EST - 5 months ago

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Feb 12, 2026, 4:00 PM EST - 5 months ago

CRISPR Therapeutics AG Annual report: Q4 2025

Feb 12, 2026, 4:00 PM EST - 5 months ago

CRISPR Therapeutics AG Earnings release: Q4 2025

Jan 12, 2026, 11:15 AM EST - 6 months ago

CRISPR Therapeutics AG Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 11:15 AM EST - 6 months ago

CRISPR Therapeutics AG Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 8:36 AM EST - 6 months ago

CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 Milestones

Jan 5, 2026, 8:30 AM EST - 6 months ago

CRISPR Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 22, 2025, 8:30 AM EST - 7 months ago

CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112™) in Autoimmune Diseases and Hematologic Malignancies

Nov 12, 2025, 11:30 AM EST - 8 months ago

CRISPR Therapeutics AG Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 10, 2025, 8:00 AM EST - 8 months ago

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

Nov 10, 2025, 7:00 AM EST - 8 months ago

CRISPR Therapeutics AG Earnings release: Q3 2025

Nov 10, 2025, 7:00 AM EST - 8 months ago

CRISPR Therapeutics AG Quarterly report: Q3 2025

Nov 9, 2025, 7:00 AM EST - 8 months ago

CRISPR Therapeutics AG Slides: Corporate presentation

Nov 8, 2025, 10:03 AM EST - 8 months ago

CRISPR gene therapy slashes 'bad' cholesterol, triglycerides by half in small study

Nov 8, 2025, 9:56 AM EST - 8 months ago

CRISPR Therapeutics Announces Positive Phase 1 Clinical Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and Lipid Lowering

Oct 10, 2025, 8:00 AM EDT - 9 months ago

CRISPR Therapeutics Presents New Preclinical Data for CTX460™ Demonstrating In Vivo Gene Correction of Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase™ Editing Platform

Oct 1, 2025, 8:00 AM EDT - 10 months ago

CRISPR Therapeutics to Present Preclinical Data on Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase Gene Editing Technology at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress

Sep 9, 2025, 4:00 PM EDT - 10 months ago

CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2025

Sep 9, 2025, 2:22 PM EDT - 10 months ago

Biotech Sector Shows No Signs of Slowing. 3 Stocks That Make the Grade.

INCY XBI XLV

Sep 9, 2025, 8:30 AM EDT - 10 months ago

CRISPR Therapeutics AG Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 8, 2025, 4:30 PM EDT - 10 months ago

CRISPR Therapeutics AG Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Aug 4, 2025, 4:15 PM EDT - 1 year ago

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

Aug 4, 2025, 12:30 PM EDT - 1 year ago

CRISPR Therapeutics AG Quarterly report: Q2 2025

Aug 4, 2025, 12:30 PM EDT - 1 year ago

CRISPR Therapeutics AG Earnings release: Q2 2025

Jul 15, 2025, 12:01 PM EDT - 1 year ago

The Big 3: ASML, GOOGL, CRSP

ASML GOOG GOOGL

Jun 26, 2025, 7:00 AM EDT - 1 year ago

CRISPR Therapeutics Reports Positive Additional Phase 1 Data for CTX310™ Targeting ANGPTL3 and Provides Update on In Vivo Cardiovascular Pipeline

Jun 23, 2025, 12:01 PM EDT - 1 year ago

The Big 3: CRSP, OKLO, GME

OKLO GME

Jun 9, 2025, 3:20 PM EDT - 1 year ago

CRISPR Therapeutics AG Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 3, 2025, 12:20 PM EDT - 1 year ago

CRISPR Therapeutics AG Transcript: 45th Annual William Blair Growth Stock Conference

May 20, 2025, 4:00 PM EDT - 1 year ago

CRISPR Therapeutics AG Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 7, 2025, 7:00 AM EDT - 1 year ago

CRISPR Therapeutics AG Slides: Corporate Presentation

May 6, 2025, 4:01 PM EDT - 1 year ago

CRISPR Therapeutics Provides First Quarter 2025 Financial Results and Announces Positive Top-Line Data from Phase 1 Clinical Trial of CTX310™ Targeting ANGPTL3

May 6, 2025, 12:30 PM EDT - 1 year ago

CRISPR Therapeutics AG Quarterly report: Q1 2025

May 6, 2025, 12:30 PM EDT - 1 year ago

CRISPR Therapeutics AG Earnings release: Q1 2025

Apr 16, 2025, 8:00 AM EDT - 1 year ago

CRISPR Therapeutics AG Proxy statement: Proxy Filing

Apr 16, 2025, 8:00 AM EDT - 1 year ago

CRISPR Therapeutics AG Proxy statement: Proxy Filing

Apr 8, 2025, 12:45 PM EDT - 1 year ago

CRISPR Therapeutics AG Transcript: 24th Annual Needham Virtual Healthcare Conference

Apr 3, 2025, 8:00 AM EDT - 1 year ago

CRISPR Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

Apr 3, 2025, 8:00 AM EDT - 1 year ago

CRISPR Therapeutics AG Proxy statement: Proxy Filing

Mar 26, 2025, 4:01 PM EDT - 1 year ago

CRISPR Therapeutics Announces Transition of Chief Operating Officer

Mar 3, 2025, 10:30 AM EST - 1 year ago

CRISPR Therapeutics AG Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 26, 2025, 8:00 AM EST - 1 year ago

CRISPR Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

Feb 11, 2025, 4:01 PM EST - 1 year ago

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 11, 2025, 4:00 PM EST - 1 year ago

CRISPR Therapeutics AG Annual report: Q4 2024

Feb 11, 2025, 4:00 PM EST - 1 year ago

CRISPR Therapeutics AG Earnings release: Q4 2024

Feb 5, 2025, 2:00 PM EST - 1 year ago

CRISPR Therapeutics AG Transcript: Guggenheim SMID Cap Biotech Conference

Jan 14, 2025, 5:15 PM EST - 1 year ago

CRISPR Therapeutics AG Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 14, 2025, 5:15 PM EST - 1 year ago

CRISPR Therapeutics AG Slides: FY 2025

Jan 8, 2025, 8:30 AM EST - 1 year ago

CRISPR Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 9, 2024, 12:00 PM EST - 1 year ago

CRISPR Therapeutics Presents Data at the 2024 American Society of Hematology (ASH) Annual Meeting

Nov 20, 2024, 11:00 AM EST - 1 year ago

CRISPR Therapeutics AG Transcript: Jefferies London Healthcare Conference 2024

Nov 14, 2024, 8:30 AM EST - 1 year ago

CRISPR Therapeutics to Present at the Jefferies London Healthcare Conference

Nov 12, 2024, 2:00 PM EST - 1 year ago

CRISPR Therapeutics AG Transcript: Guggenheim Securities Inaugural Healthcare Innovation Conference

Nov 5, 2024, 9:01 AM EST - 1 year ago

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results

Nov 5, 2024, 9:00 AM EST - 1 year ago

CRISPR Therapeutics AG Quarterly report: Q3 2024

Nov 5, 2024, 9:00 AM EST - 1 year ago

CRISPR Therapeutics AG Earnings release: Q3 2024

Aug 5, 2024, 4:01 PM EDT - 2 years ago

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results

Aug 5, 2024, 4:00 PM EDT - 2 years ago

CRISPR Therapeutics AG Quarterly report: Q2 2024

Aug 5, 2024, 4:00 PM EDT - 2 years ago

CRISPR Therapeutics AG Earnings release: Q2 2024

Jun 11, 2024, 9:20 AM EDT - 2 years ago

CRISPR Therapeutics AG Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

Jun 5, 2024, 2:00 PM EDT - 2 years ago

CRISPR Therapeutics AG Transcript: Jefferies 2024 Global Healthcare Conference

May 24, 2024, 7:40 PM EDT - 2 years ago

Final Trade: UAL, NKE, SLV & CRSP

SLV NKE UAL

May 23, 2024, 8:00 AM EDT - 2 years ago

CRISPR Therapeutics Strengthens Executive Leadership Team with Key Appointments

May 15, 2024, 12:20 PM EDT - 2 years ago

CRISPR Therapeutics AG Transcript: BofA Securities 2024 Health Care Conference

May 15, 2024, 12:20 PM EDT - 2 years ago

CRISPR Therapeutics AG Slides: FY 2024

May 9, 2024, 8:30 AM EDT - 2 years ago

CRISPR Therapeutics to Present at the Bank of America Securities Health Care Conference

May 8, 2024, 4:00 PM EDT - 2 years ago

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

May 8, 2024, 4:00 PM EDT - 2 years ago

CRISPR Therapeutics AG Quarterly report: Q1 2024

May 8, 2024, 4:00 PM EDT - 2 years ago

CRISPR Therapeutics AG Earnings release: Q1 2024

May 8, 2024, 7:00 AM EDT - 2 years ago

CRISPR Therapeutics Highlights ASGCT Oral Presentation and Announces New Programs Utilizing In Vivo Gene Editing Approach

Apr 22, 2024, 4:30 PM EDT - 2 years ago

CRISPR Therapeutics to Present Oral Presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting

Apr 10, 2024, 11:45 AM EDT - 2 years ago

CRISPR Therapeutics AG Transcript: 23rd Annual Needham Virtual Healthcare Conference

Apr 9, 2024, 8:00 AM EDT - 2 years ago

CRISPR Therapeutics AG Proxy statement: Proxy Filing

Apr 9, 2024, 8:00 AM EDT - 2 years ago

CRISPR Therapeutics AG Proxy statement: Proxy Filing

Apr 3, 2024, 8:00 AM EDT - 2 years ago

CRISPR Therapeutics to Present at the Annual Needham Virtual Healthcare Conference

Apr 1, 2024, 8:00 AM EDT - 2 years ago

CRISPR Therapeutics to Present at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting

Mar 27, 2024, 8:00 AM EDT - 2 years ago

CRISPR Therapeutics AG Proxy statement: Proxy Filing

Mar 13, 2024, 8:30 AM EDT - 2 years ago

CRISPR Therapeutics Proposes New Appointment to the Board of Directors

Mar 1, 2024, 6:21 PM EST - 2 years ago

Final Trade: HPQ, RSG, GM, CRSP

GM HPQ RSG

Feb 29, 2024, 5:02 PM EST - 2 years ago

Crispr Therapeutics CEO: Science in gene editing is moving at break-neck speed

Feb 21, 2024, 1:00 PM EST - 2 years ago

CRISPR Therapeutics AG Transcript: Citi 2024 Virtual Oncology Leadership Summit

Feb 21, 2024, 7:30 AM EST - 2 years ago

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 21, 2024, 7:00 AM EST - 2 years ago

CRISPR Therapeutics AG Annual report: Q4 2023

Feb 21, 2024, 7:00 AM EST - 2 years ago

CRISPR Therapeutics AG Earnings release: Q4 2023

Feb 15, 2024, 8:30 AM EST - 2 years ago

CRISPR Therapeutics to Present at the Citi 2024 Virtual Oncology Leadership Summit

Feb 13, 2024, 8:30 AM EST - 2 years ago

CRISPR Therapeutics Announces $280 Million Registered Direct Offering

Feb 13, 2024, 2:30 AM EST - 2 years ago

European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)

DinoFire Jul. 9 at 8:55 PM

$CRSP Patience is bitter, but its fruit is sweet.

0 · Reply

dens214 Jul. 9 at 8:37 PM

$CRSP H2,2026 day 9, 1/2 (vrtx) catalyst. Minimum positive price action.

0 · Reply

handmedown1 Jul. 9 at 8:16 PM

$CRSP Cant believe no activist investor has done anything. Is CW still holding?? She is kiss of death

0 · Reply

handmedown1 Jul. 9 at 8:14 PM

$CRSP such garbage

0 · Reply

TitsMcGeee Jul. 9 at 7:33 PM

$CRSP Buy in $40S, sell in $60S. A tale as old as time. I could have retired on trading this strategy for the last 5 years if I had any brain at all.

1 · Reply

brodobagginz Jul. 9 at 7:30 PM

$CRSP lame, lame, lame today

0 · Reply

dens214 Jul. 9 at 7:06 PM

$CRSP time for a stock buyback.

0 · Reply

BobJohnBuoy666 Jul. 9 at 4:41 PM

$CRSP needs to prove itself but as long as it stays north of the 200EMA looks to be setting up for a substantial breakout

0 · Reply

ultraviolin Jul. 9 at 4:20 PM

$CRSP $PFE Will re-enter $CRSP once it drops further

0 · Reply

handmedown1 Jul. 9 at 3:10 PM

$TWST $CRSP if only crspr had competent mgmt we would be on par with twist

0 · Reply

DegenStock Jul. 9 at 1:48 PM

$CRSP so many updates expected 2H 2026 let’s hope we start getting them soon… also I don’t remember but did we get an update for the CTX460, which was expected mid 2026? We are past mid now lol

1 · Reply

isellitgosup Jul. 8 at 6:18 PM

$CRSP At least 26% short here. If ever there is big news we could skyrocket.

2 · Reply

Nitro111 Jul. 8 at 1:52 PM

$CRSP

0 · Reply

what_it_do Jul. 8 at 1:41 PM

$CRSP damn they play too much

0 · Reply

what_it_do Jul. 8 at 1:30 PM

$CRSP hey what the fuck are you doing

0 · Reply

mikeg1999 Jul. 8 at 1:05 PM

$CRSP hate to break it, but this is just following XBI. despite casgevy approval, the market still doesnt appreciate the true value of the pipeline. $3.5B in enterprise value. swing trades are still in effect lol

0 · Reply

dileep1209 Jul. 8 at 1:33 AM

$CRSP VRTX is not trying to buy CRSP because it doesn’t fit their acquisition strategy. They want commercial-ready endocrine drugs, not high-risk gene-editing platforms. And they already get the benefits of CRSP’s technology through the CASGEVY partnership — without paying billions to acquire the entire company.

1 · Reply

BillionerOfKing Jul. 8 at 12:53 AM

$CRSP Current Stock Price: $60.80 Contracts to trade: $61.0 CRSP Jul 10 2026 Call Entry: $0.20 Exit: $0.28 ROI: 41% Hold ~25 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

Smolter Jul. 7 at 4:53 PM

$CRSP climb this mountain

0 · Reply

BobJohnBuoy666 Jul. 7 at 4:47 PM

$CRSP hell yeah

0 · Reply

Steamroller_88 Jul. 7 at 4:26 PM

$CRSP

0 · Reply

BillCheap Jul. 7 at 2:26 PM

$CRSP this stock teaches me time and time again to flip it ,.it can never hold strong gains for more than a day

1 · Reply

Market Cap	5.86B
Revenue (ttm)	3.51M
Net Income (ttm)	-581.60M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-16,569.80%
Debt to Equity Ratio	0.32

Volume	1,430,936
Avg Vol	1,733,376
Day's Range	N/A - N/A
Shares Out	96.45M
Stochastic %K	58%
Beta	1.71
Analysts	Strong Sell
Price Target	$81.75